StockNews.AI
INM
StockNews.AI
8 hrs

InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025

1. InMed Pharmaceuticals to present at Virtual Investor Forum on September 18, 2025. 2. CEO Eric A. Adams will discuss INM-901 and Alzheimer’s treatment updates. 3. Event includes 1x1 meetings for deeper investor engagement. 4. Archived webcasts will be available for those unable to attend live. 5. Company focuses on high unmet medical needs in its drug pipeline.

7m saved
Insight
Article

FAQ

Why Bullish?

The upcoming presentation can raise investor interest, similar to past investor events that led to stock price increases for other firms in the biotech sector after positive announcements.

How important is it?

The presentation's focus on INM-901, a critical pipeline drug, is likely to attract attention due to its potential in treating Alzheimer’s, which can significantly impact INM's valuation.

Why Short Term?

The investor presentation and updates will likely create immediate interest, affecting stock price in the short term, especially as INM-901 is a leading program.

Related Companies

ABUSADMSACAD
September 16, 2025 13:39 ET  | Source: Virtual Investor Conferences Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com VANCOUVER, British Columbia, Sept. 16, 2025 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that Eric A. Adams, InMed’s CEO, will present live at the Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on September 18th, 2025. DATE: September 18th    TIME: 2:00 PM ET LINK:  REGISTER HEREAvailable for 1x1 meetings: September 18-23. Please schedule 1x1 meetings here. This will be a live, interactive online event where investors are invited to ask the Company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at www.virtualinvestorconferences.com. In the presentation, Eric A. Adams, InMed’s CEO, will highlight updates and progress of InMed’s pipeline including recent data from the Company’s leading pharmaceutical program INM-901, in the treatment of Alzheimer’s, that was recently presented at Alzheimer’s Association International Conference (AAIC) 2025, the world’s leading forum for Alzheimer’s disease and dementia research. About InMed: InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three separate programs in the treatment of Alzheimer’s, ocular and dermatological indications. For more information, visit www.inmedpharma.com. About Virtual Investor Conferences®Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access.  Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. Investor Contact: Colin ClancyVice President, Investor Relations and Corporate CommunicationsT: +1.604.416.0999E: ir@inmedpharma.com Virtual Investor Conferences John M. ViglottiSVP Corporate Services, Investor AccessOTC Markets Group (212) 220-2221johnv@otcmarkets.com Cautionary Note Regarding Forward-Looking Information: This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “potential”, “possible”, “would” and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: a corporate presentation highlighting recent updates and progress with InMed’s pipeline including recent data from the Company’s lead program INM-901 in the treatment of Alzheimer’s Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed’s stand-alone business is disclosed in InMed’s Annual Report on Form 10-K, in Item 1A. of the Quarterly Report for the period ended March 31, 2025, and other filings with the Securities and Exchange Commission on www.sec.gov. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

Related News